Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II comparison of Priorix-Tetra versus Priorix + Varilrix as second-dose measles-mumps-rubella-varicella vaccination in children previously primed with MMR
2005-006065-14Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in measles, mumps, rubella and 1 more comparing Priorix-Tetra with Priorix + Varilrix (2 arms). Primary endpoint: Varicella seroconversion rate. Started Feb 2006; status: completed.
02
Drugs
GSK208136measles, mumps and rubella vaccine (live)varicella virus vaccine live
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2005-006065-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006065-14.